1. Home
  2. APPN vs NRIX Comparison

APPN vs NRIX Comparison

Compare APPN & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Appian Corporation

APPN

Appian Corporation

HOLD

Current Price

$24.73

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$14.64

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APPN
NRIX
Founded
1999
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
APPN
NRIX
Price
$24.73
$14.64
Analyst Decision
Hold
Strong Buy
Analyst Count
5
12
Target Price
$29.80
$30.50
AVG Volume (30 Days)
1.1M
961.1K
Earning Date
05-07-2026
04-08-2026
Dividend Yield
N/A
N/A
EPS Growth
101.59
N/A
EPS
N/A
N/A
Revenue
$226,743,000.00
$76,987,000.00
Revenue This Year
$13.79
N/A
Revenue Next Year
$10.56
$48.05
P/E Ratio
N/A
N/A
Revenue Growth
28.29
99.31
52 Week Low
$18.63
$8.20
52 Week High
$46.06
$22.50

Technical Indicators

Market Signals
Indicator
APPN
NRIX
Relative Strength Index (RSI) 58.42 32.11
Support Level $22.39 $11.67
Resistance Level $27.22 $17.06
Average True Range (ATR) 1.49 0.90
MACD 0.46 -0.26
Stochastic Oscillator 66.92 3.88

Price Performance

Historical Comparison
APPN
NRIX

About APPN Appian Corporation

Appian Corp is a low-code enterprise platform-as-a-service company focusing on business process management. The company's Appian platform is an integrated automation platform providing tools for organizations to design, automate, and optimize end-to-end processes and complex business operations. The company also provides maintenance and support as well as consulting services and training related to its platform. The majority of its revenue is subscription-based with the remainder from services, with much of its subscription revenue being derived from its cloud-based platform. Geographically, the company derives maximum revenue from its Domestic operations, and also has its presence Internationally.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Share on Social Networks: